Lars Fransecky

8PUBLICATIONS
75CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical virologyEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 18, 2026
Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

|Jan 06, 2026
A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Hartmut Döhner, Daniela Späth, Maral Saadati

|Dec 08, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Anne Sophie Platzbecker, Julia-Annabell Georgi, Jan Moritz Middeke

|Nov 06, 2024
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.

Leo Ruhnke, Marius Bill, Sven Zukunft

|Sep 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

Christoph Röllig, Björn Steffen, Christoph Schliemann

|Apr 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.

Hartmut Döhner, Daniela Weber, Julia Krzykalla

Pageof 2

Frequent Collaborators

4 joint publications

Christian Thiede

4 joint publications

Uwe Platzbecker

4 joint publications

Martin Bornhäuser

4 joint publications

Christoph Röllig